The Efficacy of Nanofractional Radiofrequency Device in Arm Rejuvenation and Tightening : a Pilot Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02791620 |
Recruitment Status : Unknown
Verified June 2016 by Chulalongkorn University.
Recruitment status was: Recruiting
First Posted : June 7, 2016
Last Update Posted : June 7, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Skin Tightening and Rejuvenation | Device: a nanofractional radiofrequency device | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Efficacy of Nanofractional Radiofrequency Device in Arm Rejuvenation and Tightening : a Pilot Study |
Study Start Date : | June 2016 |
Estimated Primary Completion Date : | October 2016 |
Estimated Study Completion Date : | January 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: A nanofractional radiofrequency device |
Device: a nanofractional radiofrequency device
A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
Other Name: Venus Viva, Venus concept |
- Effects of arm rejuvenation and tightening [ Time Frame: 12 weeks after the last treatment ]Determined by changing of the treated surface area (calculated from four-fixed tattoo points on the inner arm) surface area = length x width cm2
- Changing of skin laxity and elasticity [ Time Frame: 12 weeks after the last treatment ]Evaluated by skin's viscoelastic properties using Dermalab, Courage Khazaka Electronic GmbH
- Changing of skin wrinkles and laxity using photographs of subjects' baselines and 12 weeks after the last treatment by two independent board certified dermatologists [ Time Frame: 12 weeks after the last treatment ]Determined by five point scale. (1) excellent improvement (>75%), (2) good improvement (50-75%), (3) fair improvement (25-50%), (4) some improvement (10-25%) and (5) little or no improvement (0-10%)
- evaluate perceptions of treatment with a nano-fractional radiofrequency device [ Time Frame: 12 weeks after the last treatment ]using five-point scale Five point scale evaluation: (1) excellent improvement (>75%), (2) good improvement (50-75%), (3) fair improvement (25-50%), (4) some improvement (10-25%) and (5) little or no improvement (0-10%)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 1. Healthy female or male subjects, at least 30-60 years old of age 2. Subject who has BMI 18.50- 25 kg/m2 (as picture criteria above) 3. Subject has clinically evident moderate skin laxity with or without wrinkle on the upper arm 4. Subject has read and signed a written informed consent form.
Exclusion Criteria:
- 1. Patient with weight loss > 15% 2. Pregnancy or Lactation 3. History of pacemaker, defibrillator 4. History of laser resurfacing, prior radiofrequency, ultrasound or focused ultrasound on treatment areas within 1 year on the treatment area 5. History of Heat sensitivity, collagen vascular disorder disease including morphea, scleroderma, heat contact urticaria 6. History of medical illness that primary investigator thinks could interfere or influence the wound healing process 7. History of abnormal scars (keloid, hypertrophic scars) 8. History of skin cancer, radiation therapy or metal implants on treatment areas 9. Active local or systemic infection on treatment areas 10. Any other conditions that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
11. Subject is unable or unwilling to comply with the study requirements. 12. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02791620
Thailand | |
Department of Dermatology, Faculty of Medicine, Chulalongkorn University | Recruiting |
Bangkok, Thailand, 10330 | |
Contact: Marisa Pongprutthipan, MD 022564253 Dr_marisa@yahoo.com | |
Contact: Chanika Witoonchart, MD 022564253 C.kulapatrapa@gmail.com |
Responsible Party: | Chulalongkorn University |
ClinicalTrials.gov Identifier: | NCT02791620 |
Other Study ID Numbers: |
256/59 |
First Posted: | June 7, 2016 Key Record Dates |
Last Update Posted: | June 7, 2016 |
Last Verified: | June 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |